About.

A builder shaped by Glasgow, family business and a belief that responsibility should stay visible.

Varun Sharma is the Glasgow-born founder, CEO and CTO of NEUVIOR and product architect of PHARMORIS. A British-Indian entrepreneur, he builds evidence-led pharmaceutical systems while developing longer-term theses across intelligence, advanced manufacturing and extreme-environment science.

Current roles and longer-term interests are labelled separately · Reviewed 02 August 2026

The record and the thesis.

Varun Sharma is a Glasgow-born British-Indian entrepreneur and the founder, CEO and CTO of NEUVIOR Pharmaceuticals Ltd. He leads the company’s direction and is product architect of PHARMORIS, a staff-facing, human-governed medicines-operations system under controlled, non-production development.

His central thesis is that medicines systems do not need more information without ownership. They need evidence that can be identified, decisions retained by authorised people and a visible record of why an action progressed, changed or stopped. PHARMORIS is the first focused expression of that thesis. It is not presented as deployed, clinically validated or NHS-endorsed.

Varun’s approach was shaped by the practical education of family business. He has written publicly about lessons from his father’s corner shop: listen closely, understand the person in front of you and make the next action clear. He has also contributed commentary on neurodivergent entrepreneurship, medicines access and accountable pharmaceutical operations to BusinessCloud, Startups Magazine, Manufacturing Chemist and PharmaTimes.

NEUVIOR Pharmaceuticals Ltd was incorporated in Scotland in August 2025. It was lead participant on two closed Innovate UK project records: PHARMORIS and VIONIX ZERO, together carrying £74,928 in recorded grant offers in the UKRI Gateway to Research. The VIONIX ZERO record relates to completed feasibility work and is not presented as an active manufacturing or trials programme. NEUVIOR’s 2025–26 NHS Data Security and Protection Toolkit submission was published as “Standards met”; that publication is not an NHS endorsement or evidence of product deployment.

Varun’s current work remains concentrated in NEUVIOR and PHARMORIS. Beyond that operating core, he is developing longer-term theses across responsible intelligence, partner-led life-science discovery and extreme-environment research. VARUNÉ Intelligence and VARUNÉ Labs are described as discovery or predevelopment work. VYRONIS, AIRRÈ and CHRONOVA remain long-horizon research and venture concepts. No customer, facility, partnership, funding or regulated capability is implied by their inclusion.

This website makes both sides legible: what exists now and what Varun wants to build towards. Sources, dates, stage labels and limitations remain visible so readers can verify the record without mistaking ambition for outcome.

Explore the source-linked record

Principles before personality.

These principles govern how current work is described, how future ideas are staged and how uncertainty remains visible.

01

Evidence before theatre.

A claim should survive a sceptical reader, a source check and the passage of time.

02

Human authority stays visible.

Software may organise evidence and options; accountable people retain judgement and approval.

03

Focus funds ambition.

NEUVIOR and PHARMORIS come first. Future theses advance only when evidence earns the next gate.

04

Unknown remains unknown.

Uncertainty is not a branding flaw. Making it visible protects decisions, partners and reputation.